author-photo

Nageswara Rao Muddana

17

Papers

55

Citations

Citation Trend

Filter By

Papers (13) Sort By

Journal Conference Others

Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation.

2021 Psychopharmacology
Show All
- Source
- Cite
- Save
Citations (2)
First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects.

2021 Clinical Drug Investigation
Show All
- Source
- Cite
- Save
Citations (2)
SUVN‐I6107: A novel muscarinic M1 receptor‐positive allosteric modulator (M1‐PAM) for the treatment of cognitive deficits: Biomarkers (non‐neuroimaging)/Prognostic utility

2020 Alzheimers & Dementia
Show All
- Source
- Cite
- Save
Citations (0)
0760 SUVN-G3031, A Potent And Selective Histamine H3 Receptor Inverse Agonist: Safety, Tolerability And Pharmacokinetics Following Single And Multiple Ascending Doses In Healthy Adult Subjects

2020 Sleep
Show All
- Source
- Cite
- Save
Citations (0)
Absorption, Distribution, Metabolism, Excretion (ADME), Drug-drug interaction potential and Prediction of Human Pharmacokinetics of SUVN-G3031, a Novel Histamine 3 Receptor (H3R) inverse agonist in Clinical development for the treatment of Narcolepsy.

2020 European Journal of Pharmaceutical Sciences
Show All
- Source
- Cite
- Save
Citations (2)
0053 SUVN-G3031: Safety, Tolerability and Pharmacokinetics of a Potent and Selective Histamine H3 Receptor Inverse Agonist - Single and Multiple Ascending Doses in Healthy Subjects

2019 Sleep
Show All
- Source
- Cite
- Save
Citations (2)
SAFETY, TOLERABILITY AND HUMAN PHARMACOKINETICS OF SUVN-502, A POTENT AND PURE 5-HT6 RECEPTOR ANTAGONIST

2019 Alzheimers & Dementia
Show All
- Source
- Cite
- Save
Citations (0)
Safety, tolerability and pharmacokinetics of a potent and selective histamine h3 receptor inverse agonist, SUVN-G3031 following single and multiple ascending doses in healthy subjects

2019 Sleep Medicine
Show All
- Source
- Cite
- Save
Citations (0)
Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, SUVN-502, in Healthy Young Adults and Elderly Subjects

2018 Clinical Drug Investigation
Show All
- Source
- Cite
- Save
Citations (3)
SUVN-502 + DONEPEZIL + MEMANTINE (TRIPLE COMBINATION) REPRESENTS A PROMISING NEW APPROACH FOR SYMPTOMATIC TREATMENT OF ALZHEIMER’S DISEASE

2017 Alzheimers & Dementia
Show All
- Source
- Cite
- Save
Citations (1)